BR112012015202B1 - uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica - Google Patents
uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica Download PDFInfo
- Publication number
- BR112012015202B1 BR112012015202B1 BR112012015202-5A BR112012015202A BR112012015202B1 BR 112012015202 B1 BR112012015202 B1 BR 112012015202B1 BR 112012015202 A BR112012015202 A BR 112012015202A BR 112012015202 B1 BR112012015202 B1 BR 112012015202B1
- Authority
- BR
- Brazil
- Prior art keywords
- carrageenan
- iota
- infection
- neuraminidase inhibitor
- kappa
- Prior art date
Links
- 239000002911 sialidase inhibitor Substances 0.000 title claims abstract description 44
- 229940123424 Neuraminidase inhibitor Drugs 0.000 title claims abstract description 40
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 title claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 229920001525 carrageenan Polymers 0.000 claims abstract description 51
- 229940113118 carrageenan Drugs 0.000 claims abstract description 50
- 239000000679 carrageenan Substances 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 208000015181 infectious disease Diseases 0.000 claims abstract description 39
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 27
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 24
- 208000024891 symptom Diseases 0.000 claims abstract description 17
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 14
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 12
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 30
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 28
- 229960001028 zanamivir Drugs 0.000 claims description 26
- 230000000840 anti-viral effect Effects 0.000 claims description 21
- 229960003752 oseltamivir Drugs 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 13
- 230000000241 respiratory effect Effects 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 208000003322 Coinfection Diseases 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 5
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 5
- 229950004244 laninamivir Drugs 0.000 claims description 5
- 239000006193 liquid solution Substances 0.000 claims description 5
- 229960001084 peramivir Drugs 0.000 claims description 5
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 5
- 241000709661 Enterovirus Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 4
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 24
- 229940061367 tamiflu Drugs 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229960002194 oseltamivir phosphate Drugs 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- -1 carrageenan compound Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229940061374 relenza Drugs 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 208000021240 acute bronchiolitis Diseases 0.000 description 1
- 201000010550 acute laryngitis Diseases 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28214809P | 2009-12-22 | 2009-12-22 | |
| US61/282,148 | 2009-12-22 | ||
| PCT/EP2010/007726 WO2011076367A2 (en) | 2009-12-22 | 2010-12-17 | Synergistic antiviral composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012015202A2 BR112012015202A2 (pt) | 2016-04-05 |
| BR112012015202B1 true BR112012015202B1 (pt) | 2020-12-08 |
Family
ID=44063696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012015202-5A BR112012015202B1 (pt) | 2009-12-22 | 2010-12-17 | uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10022449B2 (enExample) |
| EP (1) | EP2515889B1 (enExample) |
| JP (1) | JP5902628B2 (enExample) |
| KR (1) | KR101862415B1 (enExample) |
| CN (1) | CN102652017A (enExample) |
| AU (1) | AU2010335594B2 (enExample) |
| BR (1) | BR112012015202B1 (enExample) |
| CA (1) | CA2779532C (enExample) |
| CL (1) | CL2012001695A1 (enExample) |
| DK (1) | DK2515889T3 (enExample) |
| EA (1) | EA022840B1 (enExample) |
| ES (1) | ES2531367T3 (enExample) |
| IL (1) | IL219552A (enExample) |
| MX (1) | MX2012007166A (enExample) |
| NZ (1) | NZ599839A (enExample) |
| PL (1) | PL2515889T3 (enExample) |
| PT (1) | PT2515889E (enExample) |
| SG (1) | SG181421A1 (enExample) |
| SI (1) | SI2515889T1 (enExample) |
| WO (1) | WO2011076367A2 (enExample) |
| ZA (1) | ZA201202482B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012126777A1 (en) * | 2011-03-18 | 2012-09-27 | Marinomed Biotechnologie Gmbh | Inhibition of neuraminidase activity |
| RU2469020C1 (ru) * | 2011-11-08 | 2012-12-10 | Александр Васильевич Иващенко | (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения |
| RU2520836C1 (ru) * | 2013-02-27 | 2014-06-27 | Александр Васильевич Иващенко | (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения |
| PT2898888T (pt) * | 2014-01-22 | 2019-07-16 | Visufarma B V | Composição que compreende iota-carragenina contra conjuntivite viral |
| US12594285B2 (en) | 2016-02-25 | 2026-04-07 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| EP3419629A4 (en) * | 2016-02-25 | 2019-10-30 | Applied Biological Laboratories, Inc. | COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES |
| US11304989B2 (en) * | 2017-10-06 | 2022-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Peptides for use in the treatment of viral infections |
| WO2019160261A1 (ko) * | 2018-02-14 | 2019-08-22 | (주)나노메디카 | 항바이러스 처리 방법, 항바이러스 필터, 및 이를 구비한 마스크 |
| KR102316819B1 (ko) * | 2018-04-20 | 2021-10-25 | 한미약품 주식회사 | 카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제 |
| GB2579600B (en) | 2018-12-05 | 2023-07-05 | Byotrol Plc | Anti-viral composition |
| MX2021016040A (es) * | 2019-07-03 | 2022-03-11 | Aillis Inc | Composicion farmaceutica para el tratamiento de infecciones de virus de influenza. |
| WO2021184123A1 (en) * | 2020-03-18 | 2021-09-23 | Encyt Technologies, Inc. | Compositions and methods for the treatment of coronavirus infection and respiratory compromise |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593314B1 (en) * | 1999-10-19 | 2003-07-15 | Abbott Laboratories | Neuraminidase inhibitors |
| JP2001181188A (ja) * | 1999-12-28 | 2001-07-03 | Marine Biotechnol Inst Co Ltd | インフルエンザウイルス感染阻害剤 |
| SI2101792T1 (sl) | 2006-12-05 | 2010-08-31 | Marinomed Biotechnologie Gmbh | Uporaba karagenana za zdravljenje rinovirusnih infekcij |
| EP1930015A1 (en) * | 2006-12-05 | 2008-06-11 | Marinomed Biotechnologie GmbH | Use of carrageenan for treating rhinovirus infections |
| WO2008147468A2 (en) | 2006-12-18 | 2008-12-04 | Amcol International | Compositions comprising virus-interacting layered phyllosilicates and a therapeutic agent, and methods of use |
| SI2178533T1 (sl) * | 2007-08-24 | 2013-07-31 | Marinomed Biotechnologie Gmbh | Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan |
-
2010
- 2010-12-17 AU AU2010335594A patent/AU2010335594B2/en not_active Ceased
- 2010-12-17 EP EP10810910.9A patent/EP2515889B1/en active Active
- 2010-12-17 BR BR112012015202-5A patent/BR112012015202B1/pt active IP Right Grant
- 2010-12-17 NZ NZ599839A patent/NZ599839A/en unknown
- 2010-12-17 CN CN2010800551771A patent/CN102652017A/zh active Pending
- 2010-12-17 SI SI201030883T patent/SI2515889T1/sl unknown
- 2010-12-17 EA EA201290373A patent/EA022840B1/ru unknown
- 2010-12-17 PL PL10810910T patent/PL2515889T3/pl unknown
- 2010-12-17 SG SG2012033643A patent/SG181421A1/en unknown
- 2010-12-17 MX MX2012007166A patent/MX2012007166A/es active IP Right Grant
- 2010-12-17 ES ES10810910T patent/ES2531367T3/es active Active
- 2010-12-17 KR KR1020127016072A patent/KR101862415B1/ko active Active
- 2010-12-17 DK DK10810910.9T patent/DK2515889T3/en active
- 2010-12-17 JP JP2012545143A patent/JP5902628B2/ja active Active
- 2010-12-17 US US13/513,961 patent/US10022449B2/en active Active
- 2010-12-17 PT PT10810910T patent/PT2515889E/pt unknown
- 2010-12-17 CA CA2779532A patent/CA2779532C/en active Active
- 2010-12-17 WO PCT/EP2010/007726 patent/WO2011076367A2/en not_active Ceased
-
2012
- 2012-05-03 IL IL219552A patent/IL219552A/en active IP Right Grant
- 2012-05-04 ZA ZA2012/02482A patent/ZA201202482B/en unknown
- 2012-06-21 CL CL2012001695A patent/CL2012001695A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2515889T3 (en) | 2015-03-02 |
| AU2010335594B2 (en) | 2015-05-21 |
| IL219552A0 (en) | 2012-06-28 |
| NZ599839A (en) | 2014-02-28 |
| AU2010335594A1 (en) | 2012-05-24 |
| CL2012001695A1 (es) | 2013-03-08 |
| ZA201202482B (en) | 2012-12-27 |
| SI2515889T1 (sl) | 2015-04-30 |
| US20120302522A1 (en) | 2012-11-29 |
| WO2011076367A2 (en) | 2011-06-30 |
| PT2515889E (pt) | 2015-03-20 |
| KR20120107970A (ko) | 2012-10-04 |
| SG181421A1 (en) | 2012-07-30 |
| EA022840B1 (ru) | 2016-03-31 |
| CN102652017A (zh) | 2012-08-29 |
| WO2011076367A3 (en) | 2011-09-01 |
| EP2515889A2 (en) | 2012-10-31 |
| JP5902628B2 (ja) | 2016-04-13 |
| KR101862415B1 (ko) | 2018-05-29 |
| BR112012015202A2 (pt) | 2016-04-05 |
| EA201290373A1 (ru) | 2012-11-30 |
| MX2012007166A (es) | 2012-07-23 |
| CA2779532A1 (en) | 2011-06-30 |
| JP2013515022A (ja) | 2013-05-02 |
| EP2515889B1 (en) | 2014-12-10 |
| IL219552A (en) | 2016-11-30 |
| US10022449B2 (en) | 2018-07-17 |
| CA2779532C (en) | 2018-05-22 |
| PL2515889T3 (pl) | 2015-05-29 |
| ES2531367T3 (es) | 2015-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2515889B1 (en) | Synergistic antiviral composition and use thereof | |
| US20220387455A1 (en) | Treatment of moderate to severe influenza | |
| WO2015027848A1 (zh) | 含有帕拉米韦和/或其衍生物制剂的给药方法 | |
| US11826323B2 (en) | Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| CN119700755A (zh) | 化合物在制备预防和/或治疗高原病的药物中的应用 | |
| JP5828007B2 (ja) | 局所投与型の嚥下障害改善用医薬品 | |
| CN107648249B (zh) | 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用 | |
| HK1174835A (en) | Synergistic antiviral composition and use thereof | |
| EP3906934B1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| WO2025067689A1 (en) | 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus | |
| WO2025176701A1 (en) | Novel pediatric composition of nasal dexmedetomidine | |
| WO2014199486A1 (ja) | 嚥下障害改善用医薬品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2010, OBSERVADAS AS CONDICOES LEGAIS. |